Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer

Launched by SICHUAN UNIVERSITY · Jan 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating two different surgical methods for patients diagnosed with gastric cancer who need a specific type of surgery called distal gastrectomy, which involves removing a part of the stomach. The main goal is to see if a technique called Billroth II with Braun anastomosis offers more benefits or poses more risks compared to Billroth II reconstruction alone. The researchers want to understand which approach leads to better health outcomes and safety for patients after surgery.

To participate in this trial, patients must be between 18 and 80 years old and have a confirmed diagnosis of stage I-III gastric cancer that can be surgically treated. They should be in good general health without serious heart, lung, or kidney issues and should not have any other active cancers or serious medical conditions. Participants will be closely monitored during the trial to assess their recovery and any side effects from the surgery. Importantly, this trial is not yet recruiting, so potential participants will need to wait until it officially begins.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• To be enrolled, participants must be phase I-III patients with initial treatment of radical distal gastrectomy and satisfying the following inclusion criteria:
• • 1. Histologically proven stage I-III gastric cancer, evaluated as radically resectable
• • 2. No synchronous or metachronous cancers
• • 3. Patients have signed informed consent forms
• • 4. Age 18-80 years old
• • 5. No malfunction of cardio-pulmonary, liver, and kidney, ECOG score 0-1
• • 6. No emergency surgery needed
• • Exclusion criteria
• Patients will be excluded according to the following criteria:
• • 1. Pregnant or lactating women
• • 2. Distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination
• • 3. Ascites or cachexia
• • 4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes
• • 5. Participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials
• • 6. Mental illness
• • 7. Surgical history whose influence has not been eliminated
• • 8. History of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid
• • 9. Active infection with a fever of over 38°C
• • 10. Poor compliance
• • 11. Not suitable for this trial because of other clinical or laboratory conditions determined by the researchers